| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26 |
| filingDate |
2018-06-20^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a876ceb6e85fbdbe27a2de5e888a71e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38480af892a835e542f29fd41fa920f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ddccf0178e3e7ed7c4b4485c4264ca1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4647092e9c87a91e9ddffa311f0c3c54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51f588eabe799f0a0692ba9b8474fbeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c1510544106904c08d0a8bd7c6efe99 |
| publicationDate |
2020-12-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020384119-A1 |
| titleOfInvention |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| abstract |
Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143516-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143515-A1 |
| priorityDate |
2017-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |